Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens

被引:39
作者
Baumgaertner, P
Rufer, N
Devevre, E
Derre, L
Rimoldi, D
Geldhof, C
Voelter, V
Liénard, D
Romero, P
Speiser, DE
机构
[1] Ludwig Inst Canc Res, Div Clin Oncoimmunol, Lausanne, Switzerland
[2] CHU Vaudois, Multidisciplinary Oncol Ctr, CH-1011 Lausanne, Switzerland
[3] Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland
[4] Natl Ctr Competence Res, Epalinges, Switzerland
关键词
D O I
10.1158/0008-5472.CAN-05-3793
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Clinical trials have shown that strong tumor antigen-specific CD8 T-cell responses are difficult to induce but can be achieved for T-cells specific for melanoma differentiation antigens, upon repetitive vaccination with stable emulsions prepared with synthetic peptides and incomplete Freund's adjuvant. Here, we show in four melanoma patients that ex vivo detectable T-cells and thus strong T-cell responses can also be induced against the more universal cancer-testis antigens NY-ESO-1 and Mage-A10. Interestingly, all patients had ex vivo detectable T-cell responses against multiple antigens after serial vaccinations with three peptides emulsified in incomplete Freund's adjuvant. Antigen-specific T-cells displayed an activated phenotype and secreted IFN gamma. The robust immune responses provide a solid basis for further development of human T-cell vaccination.
引用
收藏
页码:1912 / 1916
页数:5
相关论文
共 20 条
[1]   Helping the CD8+ T-cell response [J].
Bevan, MJ .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (08) :595-602
[2]   Cancer immunotherapy: A treatment for the masses [J].
Blattman, JN ;
Greenberg, PD .
SCIENCE, 2004, 305 (5681) :200-205
[3]   Structural and kinetic basis for heightened immunogenicity of T cell vaccines [J].
Chen, JL ;
Stewart-Jones, G ;
Bossi, G ;
Lissin, NM ;
Wooldridge, L ;
Choi, EML ;
Held, G ;
Dunbar, PR ;
Esnouf, RM ;
Sami, M ;
Boulter, JM ;
Rizkallah, P ;
Renner, C ;
Sewell, A ;
van der Merwe, PA ;
Jakobsen, BK ;
Griffiths, G ;
Jones, EY ;
Cerundolo, V .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (08) :1243-1255
[4]   Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen [J].
Coulie, PG ;
Karanikas, V ;
Lurquin, C ;
Colau, D ;
Connerotte, T ;
Hanagiri, T ;
Van Pel, A ;
Lucas, S ;
Godelaine, D ;
Lonchay, C ;
Marchand, M ;
van Baren, N ;
Boon, T .
IMMUNOLOGICAL REVIEWS, 2002, 188 :33-42
[5]   Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans [J].
Davis, ID ;
Chen, WS ;
Jackson, H ;
Parente, P ;
Shackleton, M ;
Hopkins, W ;
Chen, QY ;
Dimopoulos, N ;
Luke, T ;
Murphy, R ;
Scott, AM ;
Maraskovsky, E ;
McArthur, G ;
MacGregor, D ;
Sturrock, S ;
Tai, TY ;
Green, S ;
Cuthbertson, A ;
Maher, D ;
Miloradovic, L ;
Mitchell, SV ;
Ritter, G ;
Jungbluth, AA ;
Chen, YT ;
Gnjatic, S ;
Hoffman, EW ;
Old, LJ ;
Cebon, JS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (29) :10697-10702
[6]  
Huang LQ, 1999, J IMMUNOL, V162, P6849
[7]   Clinical cancer vaccine trials [J].
Jäger, E ;
Jäger, D ;
Knuth, A .
CURRENT OPINION IN IMMUNOLOGY, 2002, 14 (02) :178-182
[8]   Current developments in cancer vaccines and cellular immunotherapy [J].
Ribas, A ;
Butterfield, LH ;
Glaspy, JA ;
Economou, JS .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2415-2432
[9]   T cell vaccines for microbial infections [J].
Robinson, HL ;
Amara, RR .
NATURE MEDICINE, 2005, 11 (04) :S25-S32
[10]  
Romero P, 2001, CLIN CANCER RES, V7, p766S